Associate Professor Stephen Mahler specialises in research and development of biologic medicines. 

 Associate Professor Stephen Mahler has made significant contributions to biopharmaceutical discovery, development and delivery, including development of technology for producing human antibody biopharmaceuticals.  

Associate Professor Mahler has been a member of the editorial board of the Journal of Chemical Technology and Biotechnology since 2004; and an OzReader for the Australian Research Council since 2003, reviewing ARC Discovery, Linkage, Australian Federation Fellowship, Australian Future Fellowships and ARC Centre applications. Prior to joining the AIBN, Associate Professor Mahler was co-director of the Bioengineering Centre at the University of NSW, and secured $2 million in National Collaborative Research Infrastructure Strategy (NCRIS) funding for establishing the Recombinant Products NCRIS node at UNSW.  

Industry Engagement & Collaborations

Associate Professor Mahler has delivered short courses in biologics nationally and internationally to big pharma, biotechnology companies, regulatory agencies and universities, including Pfizer Australia; the National Pharmaceutical Control Bureau, Malaysia; and at the National Forum for Biosimilars, Brazil. He has consulted for a wide range of biotechnology companies both nationally and internationally including Pfizer and Abbott. He also has academic collaborations with University of Cambridge United Kingdom and Nanyang Technological University, Singapore in the areas of Antibody Engineering and Targeted Drug Delivery, respectively.

Key Publications

Taylor K, Howard CB, Jones ML, Sedliarou I, MacDiarmid J, Brahmbhatt H, Munro TP and Mahler SM. (2015) Nanocell targeting using engineered bispecific antibodies. mAbs. 7, 53-65.

Goodall SF, Howard CB, Jones ML, Trent Munro TP, Zhongfan Zhi Z, Montiero M and Mahler SM. (2014) An EGFR targeting immunomicelle nanoparticle self-assembled with a thermoresponsive polymer. J. Chem. Technol. and Biotechnol. DOI: 10.1002/jctb.4509.

Leow H, Jones MJ, Cheng Q, Mahler SM and McCarthy J (2014) Production and characterization of specific monoclonal antibodies binding the Plasmodium falciparum diagnostic biomarker, histidine-rich protein II Malaria Journal 13, 277-287. 

Goodall SF, Jones ML and Mahler SM. (2014) Monoclonal antibody-targeted polymeric nanoparticles for cancer therapy – future prospects. J. Chem. Technol. and Biotechnol. DOI 10.1002/jctb.4555

Munro TP, Mahler SM, Huang EP, Chin DY and Gray PP (2012) Bridging the gap: development of preclinical mAb candidates.Mabs 3, 440-452. 

Full list of publications available at UQ eSpace


Associate Professor Mahler has secured more than $2 million in Australian Research Council (ARC) funding during the past four years for projects principally associated with biologics discovery, recombinant protein production and development of targeted drug delivery systems. Since 2007, Associate Professor Mahler has been interacting with biotechnology companies and has secured research funding from industry sources. Two provisional patent applications are now in the process of being submitted.